Beximco Pharmaceuticals Limited
BXP.L · LSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | £12,299,557 | £11,713,850 | £11,340,688 | £10,987,338 |
| % Growth | 5% | 3.3% | 3.2% | – |
| Cost of Goods Sold | £6,729,105 | £6,305,742 | £6,309,502 | £6,184,085 |
| Gross Profit | £5,570,452 | £5,408,108 | £5,031,186 | £4,803,253 |
| % Margin | 45.3% | 46.2% | 44.4% | 43.7% |
| R&D Expenses | £0 | £0 | £359,588 | £0 |
| G&A Expenses | £383,929 | £304,448 | £324,136 | £333,191 |
| SG&A Expenses | £3,045,916 | £2,845,000 | £2,875,867 | £2,826,393 |
| Sales & Mktg Exp. | £2,661,987 | £2,540,552 | £2,551,732 | £2,493,202 |
| Other Operating Expenses | £0 | £0 | -£359,588 | £0 |
| Operating Expenses | £3,045,916 | £2,845,000 | £2,875,867 | £2,826,393 |
| Operating Income | £2,524,536 | £2,563,108 | £2,155,319 | £1,976,860 |
| % Margin | 20.5% | 21.9% | 19% | 18% |
| Other Income/Exp. Net | -£127,459 | -£369,223 | -£247,706 | -£261,055 |
| Pre-Tax Income | £2,397,077 | £2,193,885 | £1,907,613 | £1,715,805 |
| Tax Expense | £553,948 | £502,003 | £415,568 | £349,247 |
| Net Income | £1,829,812 | £1,680,570 | £1,478,628 | £1,364,518 |
| % Margin | 14.9% | 14.3% | 13% | 12.4% |
| EPS | 4.1 | 3.77 | 3.31 | 3.06 |
| % Growth | 8.8% | 13.9% | 8.2% | – |
| EPS Diluted | 4.1 | 3.77 | 3.31 | 3.06 |
| Weighted Avg Shares Out | 446,112 | 446,112 | 446,112 | 446,112 |
| Weighted Avg Shares Out Dil | 446,112 | 446,112 | 446,112 | 446,112 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £209,534 | £278,444 | £298,970 | £289,030 |
| Depreciation & Amortization | £506,328 | £500,353 | £202,659 | £496,188 |
| EBITDA | £2,606,611 | £2,952,621 | £2,260,978 | £2,386,147 |
| % Margin | 21.2% | 25.2% | 19.9% | 21.7% |